ASCO 2021 | Final results from DESTINY-CRC01: T-Dxd in HER2-expressing mCRC

Mohamed E. Salem, MD, Levine Cancer Institute, Charlotte, NC, talks on the findings of DESTINY-CRC01 (NCT03384940), a Phase II, multicenter, open-label study investigating the activity of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.